欧洲疾控中心-欧洲2025_26冬季保护婴儿免受呼吸道合胞病毒病侵害的快速科学建议（英）

Suggested citation: European Centre for Disease Prevention and Control. Rapid scientific advice on protecting infants against respiratory syncytial virus disease for the European 2025/26 winter season – November 2025. Stockholm: ECDC; 2025. Stockholm, November 2025 ISBN 978-92-9498-839-3; doi: 10.2900/0816037; Catalogue number TQ-01-25-069-EN-N Key messages The 2025/26 season for respiratory diseases is starting in Europe, marked by increased detections of respiratory syncytial virus (RSV) in several countries and rising rates of influenza-like illness infections in primary care settings. In the coming weeks and months, groups who are vulnerable to severe illness from respiratory diseases, particularly infants, are at risk of infection. This document outlines effective ways for European Union and European Economic Area (EU/EEA) countries to mitigate the impact of RSV disease in infants through immunisation interventions. The target audience for this document is policymakers and those working in public health institutes. RSV among infants in the EU/EEA • RSV is a common respiratory virus which disproportionally affects newborns and infants, with infants under six months of age being at high risk of experiencing severe infections. • Severe RSV illness, especially among babies born prematurely or with chronic lung disease, can result in bronchiolitis or pneumonia requiring hospitalisation, and on rare occasions can lead to death. • During the 2024/2025 winter season, half of the detected RSV infections occurred in children 0-4 years of age. Infants 0–2 months of age accounted for a large proportion of admissions to intensive care units. Immunisation interventions to protect infants from RSV disease • Since 2022, the EU has authorised safe and effective RSV immunisation products to prevent RSV disease in infants. These include long-acting monoclonal antibodies (mAbs) for infants and maternal vaccines for pregnant people. • Twenty-three EU/EEA countries recommend RSV immunisation and 19 have funded long-acting mAbs programmes. Sixteen countries recommend universal long-acting mAbs for all infants and three countries recommend long-acting mAbs for infants at high risk of severe illness. • Three countries use maternal vaccination exclusively and five countries offer it as an alternative alongside long-acting mAbs. ECDC advice to strengthen RSV prevention interventions in EU/EEA countries As the 2025/26 RSV season is starting in Europe, ECDC recommends the following interventions to strengthen the protection of infants against RSV disease: • Countries should raise awareness in the community and among healthcare providers about the risk of RSV to infants, the risk factors for more severe disease in infants and children, and the availability of immunisation and information on other preventative measures such as maintaining good hygiene and respiratory etiquette. ECDC ASSESSMENT Rapid scientific advice on protecting infants against respiratory syn